Notícias e Atividades da Genetix Biotherapeutics

Genetix Biotherapeutics é uma empresa listada sob o símbolo BLUE (US).

Fusão, aquisição e financiamento envolvendo Genetix Biotherapeutics.

• Genetix Biotherapeutics and The Carlyle Group have announced they will merge  (publicado em 26 de maio de 2025)..

Veja o organograma con seus 9 executivos principais

Biografias mais buscadas da Genetix Biotherapeutics

• David Meek, Chief Executive Officer
• Julie Batal, Vice President, Regulatory Labeling, Advertising and ...
• Andrea Walton, Chief People Officer

Criar um alerta
para seguir os movimentos de executivos da Genetix Biotherapeutics.

Genetix Biotherapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Genetix Biotherapeutics

• press releases | bluebird bio, Inc.
• FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions | bluebird bio, Inc.
• FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy | bluebird bio, Inc.
• bluebird bio stock trading halted today June 9th and tomorrow June 10th | bluebird bio, Inc.
• bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting | bluebird bio, Inc.
• bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress | bluebird bio, Inc.
• bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) - bluebird bio, Inc.
• bluebird bio to Present at Jefferies Cell Therapy Virtual Summit - bluebird bio, Inc.
• bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency - bluebird bio, Inc.
• U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) - bluebird bio, Inc.
• View more press releases Close

Redes sociais sobre Genetix Biotherapeutics

• Genetix Biotherapeutics na Wikipedia, Google News e Yahoo Finance
• Genetix Biotherapeutics na LinkedIn, X (Twitter) e YouTube